Musculoskeletal Ultrasound in Patients With Hematologic Malignancies
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
This study evaluates the role and diagnostic value of musculoskeletal ultrasonography (MSUS) in adult patients with hematologic malignancies who present with musculoskeletal symptoms.
Hematologic malignancies (such as leukemia, lymphoma, and multiple myeloma) frequently involve the musculoskeletal system through bone marrow infiltration, bone destruction, or soft-tissue lesions. Musculoskeletal ultrasound is a non-invasive, radiation-free, and high-resolution imaging technique that allows real-time evaluation of joints, muscles, tendons, bursae, and superficial bone changes.
In this study, adult participants with confirmed blood cancers presenting with symptoms such as localized bone pain, joint swelling, muscle pain, or soft-tissue swelling will undergo a dedicated ultrasound examination of symptomatic areas. The study aims to characterize the patterns of musculoskeletal involvement (including cortical breaks, periosteal changes, soft-tissue masses, synovitis, and vascularity on Doppler imaging) and determine how these findings correlate with disease type, clinical presentation, and laboratory parameters.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients (aged 18 years or older) with a confirmed diagnosis of hematologic malignancy (leukemia, lymphoma, or multiple myeloma) established by bone marrow examination, histopathology, and/or immunophenotyping.
Patients presenting with musculoskeletal symptoms and undergoing musculoskeletal ultrasonography for the assessment of musculoskeletal involvement at diagnosis or during follow-up.
Patients willing and able to provide written informed consent.
Disqualifiers
Patients with a prior or concurrent solid organ malignancy with known skeletal metastasis.
Patients with a history of major musculoskeletal trauma, orthopedic surgery, or active musculoskeletal infection affecting the examined region.
Patients with other connective tissue diseases (e.g., systemic lupus erythematosus, systemic sclerosis).
Patients with other inflammatory arthropathies (e.g., psoriatic arthritis, ankylosing spondylitis, reactive arthritis).
Trial population
Adult patients aged 18 years or older with a confirmed diagnosis of hematologic malignancy (leukemia, lymphoma, or multiple myeloma) established by bone marrow examination, histopathology, and/or immunophenotyping, identified through the Clinical Hematology Unit registry at Assiut University Hospital, who present with musculoskeletal symptoms and undergo musculoskeletal ultrasound evaluation.
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
50 Participants
are grouped into 1 trial groupGroup A: Patients with Hematologic Malignancies
Trial outcomes
Primary outcomes
1
Percentage of Participants with Abnormal Musculoskeletal Ultrasonographic Findings
The percentage of participants exhibiting at least one abnormal sonographic finding on B-mode and color/power Doppler musculoskeletal ultrasound in symptomatic regions. Abnormal findings include cortical breaks/erosions, periosteal elevation/subperiosteal collections, focal soft-tissue or intramuscular masses/infiltrative lesions, joint effusion, synovial thickening/hypertrophy, tenosynovitis, or increased Doppler flow vascularity.
Time frame
BaselineLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: